About IAVI
IAVI is a company based in New York (United States) founded in 1996. It operates as a Donation / Grant-Based. IAVI offers products and services including HIV Vaccines, HIV Antibodies, Tuberculosis Vaccines, Lassa Virus Vaccine, and Marburg Virus Vaccine.
- Headquarter New York, United States
-
Sectors
Government & Social Sector
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name International Aids Vaccine Initiative, Inc.
- Date of Incorporation 27 Nov, 2013
- Jurisdiction Gurgaon, Haryana, India
-
Annual Revenue
$111.73 K (USD)0as on Mar 31, 2017
-
Net Profit
-$513.29 (USD)0as on Mar 31, 2017
-
EBITDA
-$111.76 K (USD)0as on Mar 31, 2017
-
Latest Funding Round
$143.32 M (USD), Grant
May 23, 2022
-
Investors
HHS
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IAVI
IAVI offers a comprehensive portfolio of products and services, including HIV Vaccines, HIV Antibodies, Tuberculosis Vaccines, Lassa Virus Vaccine, and Marburg Virus Vaccine.
HIV vaccines are developed to prevent HIV acquisition.
HIV antibodies are researched to combat HIV infection.
TB vaccines are advanced for global health protection.
Lassa vaccine is developed for West African outbreaks.
Marburg vaccine is created to address deadly outbreaks.
People of IAVI
Unlock access to complete
Leadership Team
17 people
Product Management Team
11 people
Software Development Team
6 people
Data Analysis and Operations Team
4 people
Senior Team
2 people
Operations Team
1 people
Human Resources and Administration
1 people
Legal and Compliance
1 people
Unlock access to complete
Funding Insights of IAVI
Investors in IAVI
IAVI has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, USAID and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Company provides funding for clinical research on infectious diseases
|
Locked | Locked | Locked |
Investor details for IAVI
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IAVI
Investment portfolio details for IAVI
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IAVI
Detailed financials for IAVI
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Iavi Comparisons
Peer comparison for IAVI
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IAVI
Detailed competitors of IAVI
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Iavi
Complete news archive for IAVI
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IAVI
IAVI was founded in 1996 and raised its 1st funding round 10 years after it was founded.
IAVI is headquartered in New York, United States. It is registered at New York, New York, United States.
Mark Feinberg is the current CEO of IAVI.
Annual revenue of IAVI is $111.73K as on Mar 31, 2017.
IAVI, a nonprofit scientific research organization, is dedicated to the development of vaccines and antibodies targeting HIV, tuberculosis, and emerging infectious diseases such as Lassa, Marburg, and Sudan viruses. Research and development efforts are conducted across global hubs in Africa, Europe, India, and the United States. Solutions are advanced through preclinical and clinical trials, with a full-circle approach from grassroots to legislative advocacy. Collaboration with academic, biotech, and global health partners is emphasized to ensure affordable and accessible public health solutions. Policy and community engagement initiatives are also pursued to support vaccine access in high-need regions.
IAVI offers HIV Vaccines, HIV Antibodies, Tuberculosis Vaccines, Lassa Virus Vaccine, and Marburg Virus Vaccine.
IAVI has 5 investors. Key investors include HHS, USAID, European Union, CEPI, and EDCTP.